R B International Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: R B International Pharmaceutical Export Portfolio Dataset — 2 Products, $82.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

R B International — Pharmaceutical Exporter Profile (2026) | 2 Products, $82.3K Trade | TransData Nexus

R B International

Indian Pharmaceutical Exporter · Biologics & Immunotherapy Specialist · $82.3K Total Trade · DGFT Verified

R B International is an Indian pharmaceutical exporter with a total trade value of $82.3K across 2 products in 2 therapeutic categories. Based on 17 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ustekinumab ($74.6K), Cladribine ($7.7K), .

R B International — Export Portfolio & Destination Treemap

R B International pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is R B International? — Company Overview & Market Position

R B International is a pharmaceutical exporter based in Nagpur, Maharashtra, India. Established in 2010, the company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The firm's corporate identification number (CIN) is 27AATFR2903C1Z8, and it operates under the GST registration number 27AATFR2903C1Z8. The company is privately held, with Mr. Mayur Rathi serving as the proprietor. R B International's annual turnover is estimated to be between 1.5 to 5 crore INR, indicating a moderate scale of operations. The company maintains a modest workforce, with up to 10 employees, reflecting its focus on specialized pharmaceutical exports. For more information, R B International can be contacted via email at export@rbinternational.co or by phone at +91 8856867763. (rbinternational.co)

What Does R B International Export? — Product Portfolio Analysis

Top Products by Export Value

1Ustekinumab$74.6K 2Cladribine$7.7K

Product Portfolio — Top 2 by Export Value

R B International exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ustekinumab	Biologics & Immunotherapy	$74.6K	14	5.9%	5
2	Cladribine	Advanced Oncology	$7.7K	3	3.3%	7

R B International exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $82.3K. The top category is Biologics & Immunotherapy (90.6% of portfolio), followed by Advanced Oncology (9.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

R B International — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

R B International operates from Nagpur, Maharashtra, India, where it manages its export operations. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details about manufacturing facilities are not publicly disclosed, the company's focus on exporting finished formulations suggests that it collaborates with contract manufacturers or sources products from third-party manufacturers. This approach allows R B International to offer a diverse range of pharmaceutical products without the overhead associated with owning manufacturing facilities. The company's product portfolio includes items such as Pirfenex 200mg Tablets, Hyponat O 15 Tablet, Clenbute 40 Mg, and Valcivir Valacyclovir 1000mg Tablet, indicating a focus on both generic and branded pharmaceutical products.

3Key Leadership

R B International is led by Mr. Mayur Rathi, who serves as the proprietor of the company. Specific details about other key executives are not publicly available. Mr. Rathi's leadership is central to the company's operations, focusing on the export of finished pharmaceutical formulations. Under his guidance, R B International has established itself as a specialized exporter in the pharmaceutical sector, catering to various international markets. The company's emphasis on quality and reliability in its product offerings reflects Mr. Rathi's commitment to meeting the precise pharmaceutical requirements of healthcare providers and patients globally.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does R B International Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

R B International's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details about the company's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed, the company's product offerings suggest potential interest in these markets. The United States, for instance, is a significant destination for pharmaceutical exports, with India being a major supplier of generic medicines. However, entering these markets requires compliance with stringent regulatory standards, including approvals from agencies such as the U.S. Food and Drug Administration (FDA) and adherence to Good Manufacturing Practice (GMP) certifications. R B International's focus on exporting finished formulations indicates a strategic approach to meet the demands of these regulated markets, potentially through partnerships with contract manufacturers or sourcing products from facilities that hold the necessary certifications. The company's emphasis on quality and reliability aligns with the expectations of healthcare providers and patients in these regions.

2Emerging Markets

R B International's export strategy includes targeting emerging markets in Africa, Latin America, and Southeast Asia. India's pharmaceutical industry has a significant presence in these regions, supplying a substantial portion of the demand for generic medicines and vaccines. For instance, India caters to 40% of the generic medicines demand in the U.S. and 25% of all medication in the UK. R B International's focus on finished pharmaceutical formulations positions it to meet the needs of these markets, where there is a growing demand for affordable and high-quality healthcare products. The company's commitment to quality and reliability aligns with the expectations of healthcare providers and patients in these regions, enabling it to establish a strong presence in emerging markets.

R B International — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding R B International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on exporting finished pharmaceutical formulations suggests that it may source products from manufacturers that hold the necessary FDA approvals and certifications. Entering the U.S. market requires compliance with FDA regulations, including obtaining approvals for drug products and manufacturing facilities. R B International's emphasis on quality and reliability indicates a potential commitment to meeting these regulatory standards, possibly through partnerships with compliant manufacturers.

2WHO & EU GMP

Specific information regarding R B International's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's focus on exporting finished pharmaceutical formulations suggests that it may collaborate with manufacturers who possess these certifications. WHO prequalification and EU GMP certifications are essential for accessing international markets, particularly in regions with stringent regulatory requirements. R B International's commitment to quality and reliability aligns with the standards set by these certifications, indicating a potential strategy to source products from compliant manufacturers to meet the demands of global markets.

R B International — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

R B International operates in a competitive landscape characterized by numerous pharmaceutical exporters in India. Major players in the Indian pharmaceutical export market include Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy's Laboratories Limited. These companies have established significant market shares and possess extensive product portfolios. R B International differentiates itself by focusing on the export of finished pharmaceutical formulations, catering to specific therapeutic areas such as oncology. This specialization allows the company to target niche markets and build strong relationships with healthcare providers and patients seeking specialized treatments. By emphasizing quality and reliability, R B International aims to carve out a distinct position in the competitive pharmaceutical export sector.

2Key Differentiators

R B International's key differentiators include its specialization in exporting finished pharmaceutical formulations, particularly in the oncology segment. The company's product portfolio features items such as Pirfenex 200mg Tablets, Hyponat O 15 Tablet, Clenbute 40 Mg, and Valcivir Valacyclovir 1000mg Tablet, indicating a focus on both generic and branded pharmaceutical products. This specialization enables R B International to cater to the precise pharmaceutical requirements of cancer patients, oncologists, hematologists, hospitals, medical institutions, and health systems. The company's commitment to quality and reliability further strengthens its competitive advantage, ensuring that its products meet the expectations of healthcare providers and patients globally.

Frequently Asked Questions — R B International

How many pharmaceutical products does R B International export from India?

R B International exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ustekinumab ($74.6K), Cladribine ($7.7K). Total export value is $82.3K.

What is R B International's total pharmaceutical export value?

R B International's total pharmaceutical export value is $82.3K, based on 17 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does R B International cover?

R B International exports across 2 therapeutic categories. The largest are Biologics & Immunotherapy (90.6%, 1 products), Advanced Oncology (9.4%, 1 products).

Get Full R B International Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.